专题研究(Monographic Study)

胆管细胞癌术后替吉奥化疗的近、远期疗效观察

Published at: 2016年第25卷第8期

李晓宁 1 , 史健 2 , 孙超 3 , 徐志宏 2
1 河北医科大学第四医院放疗科,河北 石家庄 050011
2 河北医科大学第四医院肿瘤科,河北 石家庄 050011
3 河北医科大学第四医院肝胆外科,河北 石家庄 050011
通讯作者 健 史 Email: shi_jian@21cn.com
DOI: 10.3978/j.issn.1005-6947.10.3978/j.issn.1005-6947.2016.08.010
基金:

摘要

目的:探讨胆管细胞癌患者术后替吉奥化疗的临床效果。方法:选取87例根治术后的胆管细胞癌患者为研究对象,按患者意愿,42例接收术后替吉奥化疗(化疗组),45例不接受化疗(非化疗组),比较两组患者的近期效果及远期预后差异。结果:化疗组化疗后的血清KL-6蛋白、CA19-9、CA125水平较本组化疗前及非化疗组均明显降低(均P<0.05);化疗过程中主要毒副反应为消化道不良(35.71%)、贫血(14.29%)、色素沉着(14.29%),均为轻度;两组术后1年无瘤生存率、总生存率比较差异均无统计学意义(均P>0.05);但化疗组术后3年的无瘤生存率、总生存率均明显高于非化疗组(28.57% vs. 11.11%;42.86% vs. 22.22%,均P<0.05);化疗组患者术后中位无瘤生存时间、总生存时间分别为13.7、21.5个月,均明显长于非化疗组(9.8、16.4个月)(均P<0.05)。结论:胆管细胞癌患者术后采用替吉奥进化疗对于降低肿瘤标志物水平,延长患者的生存时间具有积极作用。


Observation of short- and long-term effects of postoperative chemotherapy with tegafur/gimeracil/oteracil (S-1) on cholangiocarcinoma

Abstract

Objective: To investigate the clinical efficacy of postoperative chemotherapy with tegafur/gimeracil/oteracil (S-1) in patients with cholangiocarcinoma. Methods: Eighty-seven patients with cholangiocarcinoma after radical resection were selected as study subjects. According to patients’ preferences, 42 cases received postoperative S-1 chemotherapy (chemotherapy group), and 45 cases did not receive any postoperative chemotherapy (non-chemotherapy group). The short-term effects and long-term results between the two groups of patients were compared. Results: The serum levels of KL-6 protein, CA19-9 and CA125 after chemotherapy were significantly reduced in chemotherapy group compared with those in non- chemotherapy group (all P<0.05). The main toxic and side effects during chemotherapy were dyspepsia (35.71%), anemia (14.29%) and pigmentation (14.29%), all of which were minor degrees of severity. The 1-year disease-free survival and overall survival rates showed no statistical difference between the two groups (both P>0.05), but the 3-year disease-free survival and overall survival rates in chemotherapy group were significantly higher than those in non-chemotherapy group (28.57% vs. 11.11%; 42.86% vs. 22.22%, both P<0.05). The median disease-free survival time and overall survival time was 13.7 and 21.5 months respectively, and both were significantly longer than those in non-chemotherapy group (9.8 and 16.4 months) (both P<0.05). Conclusion: In cholangiocarcinoma patients, postoperative S-1 chemotherapy has beneficial effects on reducing tumor marker levels and prolonging survival time.


comments powered by Disqus

全文

引用

引用本文: 晓宁 李, 健 史, 超 孙, 志宏 徐. 胆管细胞癌术后替吉奥化疗的近、远期疗效观察 [J]. 中国普通外科杂志, 2016, 25(8): 1145-1150.
Cite this article as: LI Xiaoning, SHI Jian, SUN Chao, XU Zhihong . Observation of short- and long-term effects of postoperative chemotherapy with tegafur/gimeracil/oteracil (S-1) on cholangiocarcinoma [J]. Chin J Gen Surg, 2016, 25(8): 1145-1150.